Homoeopathy in Depression, Anxiety & Stress in NCD patients

Effectiveness of Individualized Homoeopathic Medicines in management of Depression, Anxiety & Stress in patients with non- communicable diseases A Multicentric randomized placebo- controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080382

Enrollment

786

Registered

2025-02-12

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F419- Anxiety disorder, unspecified

Interventions

Intervention1: Homeopathy: Individualized Homeopathic medicines will be given. The dose of the medicine will be in centisimal potency in the form of globules (4 globules/dose). Frequency of the medici

Eligibility

Inclusion criteria

Inclusion criteria: Both genders and Age from 18 to 70 years. Diagnosed cases of non-communicable diseases on medication. Mild, Moderate & Severe cases on DASS-21 Scale. Patients willing to participate in the study.

Exclusion criteria

Exclusion criteria: Patients suffering from any other known psychiatric and neurocognitive disorders (except depression, anxiety and stress). Patient under extremely severe category on DASS-21 score. Patients with uncontrolled NCDs even after medication. Patients suffering from communicable diseases like HIV,TB, Hepatitis, Leprosy etc. Patients suffering from complications of NCDs like Diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, Heart attack, Stroke, Acute limb ischaemia, acute respiratory distress syndrome, rheumatic heart disease, deep vein thrombosis, cor pulmonale, status asthmaticus, spontaneous pneumothorax, severe anaemia/neutropenia/sepsis/metastasis in cancer or any other Systemic diseases. Pregnant and Lactating women

Design outcomes

Primary

Measure	Time frame
To evaluate the effectiveness of individualized homoeopathic medicines in the management of Depression, Anxiety & Stress in patients with non-communicable diseases using DASS21 score post interventionTimepoint: Primary Outcome will be assessed at Baseline, after 2 weeks of Baseline and then every month for 6 months.	—

Secondary

Measure	Time frame
1.To assess the changes in Quality of Life of patients using WHOQOL Bref Scale. 2.To assess the changes in Depression, Anxiety & Stress along with changes in respective NCDs using validated scales & measures. Timepoint: WHO QOL Bref Scale & Investigations will be assessed at Baseline, 3 months & 6 months. Disease specific scales will be assessed at Baseline, after 2 weeks, then every month for 6 months.	—

Measure

Time frame

1.To assess the changes in Quality of Life of patients using WHOQOL Bref Scale. 2.To assess the changes in Depression, Anxiety & Stress along with changes in respective NCDs using validated scales & measures. Timepoint: WHO QOL Bref Scale & Investigations will be assessed at Baseline, 3 months & 6 months. Disease specific scales will be assessed at Baseline, after 2 weeks, then every month for 6 months.

—

Countries

India

Contacts

Public ContactDr Bharti Wadhwa

Central Council for Research in Homoeopathy

bhartiwadhwa@gmail.com09818262049

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026